scispace - formally typeset
D

Dharma R. Thapa

Researcher at University of California, Los Angeles

Publications -  12
Citations -  911

Dharma R. Thapa is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Transactivation & Beta defensin. The author has an hindex of 11, co-authored 12 publications receiving 869 citations. Previous affiliations of Dharma R. Thapa include Biogen Idec.

Papers
More filters
Journal ArticleDOI

Differential regulation of beta-defensin expression in human skin by microbial stimuli.

TL;DR: During inflammation, epidermal expression of β-defensins is mediated by at least three different mechanisms, which are distinct from each other and from the IL-1-dependent induction of hBD-2 expression.
Journal ArticleDOI

Urinary hepcidin in congenital chronic anemias.

TL;DR: Patients with congenital chronic anemias have high levels of hepcidin, a regulator for iron homeostasis, which is induced by inflammation and iron burden and suppressed by anemia and hypoxia.
Journal ArticleDOI

Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor

TL;DR: It is found that sterile wounding initiates an innate immune response that increases resistance to overt infection and microbial colonization through activation of the epidermal growth factor receptor.
Journal ArticleDOI

Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site.

TL;DR: It is shown that s-hemojuvelin is released by a proprotein convertase through the cleavage at a conserved polybasic RNRR site and could be one of the mediators of hepcidin regulation by iron.
Journal ArticleDOI

Longitudinal analysis of peripheral blood T cell receptor diversity in patients with systemic lupus erythematosus by next-generation sequencing

TL;DR: A significant decrease in T cell repertoire diversity was observed in PB of SLE patients compared to HC, and without a priori knowledge of disease-specific clones, monitoring TCR repertoire in PB from Sle patients is not likely to be useful to predict changes in disease activity.